Prospective Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Jan 14, 2022; 28(2): 263-274
Published online Jan 14, 2022. doi: 10.3748/wjg.v28.i2.263
Figure 1
Figure 1 Patient flowchart of hepatitis C virus treatment with a simplified pan-genotypic directly-acting antivirals regimen in Penghu Prison. HCV: Hepatitis C virus; DAA: Directly-acting antivirals; SOL/VEL: Sofosbuvir/velpatasvir; GEL/PIB: Glecaprevir/pibrentasvir; EOTVR: Virological response at end-of-treatment; SVR12: Sustained viral response at post-treatment wk 12.

  • Citation: Chen CT, Lu MY, Hsieh MH, Tsai PC, Hsieh TY, Yeh ML, Huang CI, Tsai YS, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Huang CF, Huang JF, Dai CY, Chuang WL, Shih YL, Yu ML. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. World J Gastroenterol 2022; 28(2): 263-274
  • URL: https://www.wjgnet.com/1007-9327/full/v28/i2/263.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v28.i2.263